The USPTO’s Patent Trial and Appeal Board instituted Merck’s (MRK) patent grant review against Halozyme’s (HALO) MDASE patents after Merck filed a Petition requesting post-grant review of claims 1-21 of U.S. Patent No. 11,952,600, according to a post to the site of the USPTO. In consideration of “the Petition, Preliminary Response, Reply, Sur-Reply, and the evidence of record, we determine that the information presented shows that it is more likely than not that Petitioner would prevail in establishing unpatentability of claims 1-4 and 8-21 of the ‘600 patent,” the board decision stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme’s Strategic Positioning and Market Potential Drive Buy Rating
- Halozyme announces EC approval of Bristol Myers’ Opdivo developed with Enhanze
- Optimistic Buy Rating for Halozyme Amid Price Control Concerns
- Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
- Hold Rating Issued Amid Uncertainty in Drug Pricing Regulations Impacting Halozyme